EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of adjunctive dihydropyridine calcium channel blockers on mental health outcomes in people with severe mental illness: A target trial emulation in English electronic health records

Naomi Launders iD, Alvin Richards-Belle, Stephanie M Wu, Kenneth K C Man, Ian C K Wong, David P J Osborn iD, Joseph F Hayes iD

Journal of Psychopharmacology · 2026

DOI: 10.1177/02698811261473408 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Psychopharmacology, 2026. Verfasst von Naomi Launders und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Psychiatry, University College London, UK. Hauptthemen laut MEDLINE: Calcium Channel Blockers, Dihydropyridines, Self-Injurious Behavior, Mental Disorders. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UK Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dihydropyridine calcium channel blockers have been implicated in both symptom improvement and exacerbation in pre-existing severe mental illness (SMI). We aimed to test the hypothesis that blood-brain barrier penetrant dihydropyridines (DHPs) reduce rates of mental health hospitalisation and self-harm compared to non-penetrant DHPs.

Methods

We used English electronic health records (Clinical Practice Research Datalink) to conduct a target trial emulation study in people with schizophrenia, bipolar disorder or other psychosis. We compared admissions for mental health and self-harm in those prescribed blood-brain barrier penetrant (intervention) and non-penetrant DHPs (control). Our primary endpoint was a 12-month intention-to-treat analysis using covariate adjustment. We additionally completed overlap weighting, per-protocol analyses and negative outcome controls.

Results

We included 918 people prescribed blood-brain barrier penetrant DHPs and 3384 prescribed amlodipine (control). In the primary covariate-adjusted intention-to-treat analysis, there was no clear evidence of a difference in rates of combined mental health admissions and self-harm events (adjusted hazard ratio (HR): 1.22; 95% confidence interval (CI): 0.78–1.91 at 12 months). In a pre-specified sensitivity analysis using overlap weighting, self-harm event rates were elevated in the intervention group at 12 months (HR: 2.10; 95% CI: 1.13–3.94); however, the equivalent covariate-adjusted estimate showed no clear difference (HR: 1.81; 95% CI: 0.52–6.26).

Conclusion

In people with SMI, blood-brain barrier penetrant DHPs were not associated with reduced mental health hospitalisations or self-harm events compared to those treated with amlodipine, though estimates were imprecise. This active comparator design cannot distinguish between absence of effect or equivalent benefit of both drug classes. There are peripheral pathways through which DHPs may impact psychiatric symptoms and these require further exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcium Channel BlockersDihydropyridinesSelf-Injurious BehaviorMental DisordersSchizophreniaPsychotic DisordersHumansElectronic Health RecordsFemaleMaleAdultHospitalizationAmlodipineBlood-Brain BarrierMiddle AgedBipolar Disorder

Stichwörter der Autor:innen

calcium channel blockerssevere mental illnesstarget trial emulation

Substanzen

Calcium Channel BlockersDihydropyridinesAmlodipine

Autor:innen und Institutionen

  • Division of Psychiatry, University College London, UK.
  • Research Department of Practice and Policy, School of Pharmacy, University College London, UK.
  • Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, UK.
  • Li Ka Shing Faculty of Medicine, Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, University of Hong Kong, Hong Kong.
  • Advance Data Analytics for Medical Science Limited, Hong Kong Special Administrative Region, China.
  • Aston Centre of Excellence in Pharmacotherapy Optimisation and Pharmacoepidemiology Research, Aston Pharmacy School, Aston University, Birmingham, UK.

ORCID-Profile: Naomi Launders, David P J Osborn, Joseph F Hayes

Förderung

  • UK Research and Innovation

Zitieren

APA

Launders, N., Richards-Belle, A., Wu, S. M., Man, K. K. C., Wong, I. C. K., Osborn, D. P. J., & Hayes, J. F. (2026). Impact of adjunctive dihydropyridine calcium channel blockers on mental health outcomes in people with severe mental illness: A target trial emulation in English electronic health records. Journal of Psychopharmacology. https://doi.org/10.1177/02698811261473408

Vancouver

Launders N, Richards-Belle A, Wu SM, Man KKC, Wong ICK, Osborn DPJ, et al. Impact of adjunctive dihydropyridine calcium channel blockers on mental health outcomes in people with severe mental illness: A target trial emulation in English electronic health records. Journal of Psychopharmacology. 2026. doi:10.1177/02698811261473408

BibTeX
@article{Launders2026,
  author = {Launders, Naomi and Richards-Belle, Alvin and Wu, Stephanie M and Man, Kenneth K C and Wong, Ian C K and Osborn, David P J and Hayes, Joseph F},
  title = {Impact of adjunctive dihydropyridine calcium channel blockers on mental health outcomes in people with severe mental illness: A target trial emulation in English electronic health records},
  journal = {Journal of Psychopharmacology},
  year = {2026},
  doi = {10.1177/02698811261473408}
}
Kostenlos starten →